Fred Hassan
Fred Hassan
Fred Hassanis a managing director at Warburg Pincus, which he joined in 2011. He was the Chairman of the Board and Chief Executive Officer of pharmaceutical company Schering-Plough from 2003 until November 3, 2009, when the company completed its merger with Merck & Co. Hassan was the Chairman of the Board of Bausch & Lomb from March 2010 until its sale in 2013. On October 29, 2009 Time Warner announced that Hassan would join their Board of Directors...
breadth build company continue deliver high looking mode moving strength survive thrive track
Looking ahead, we continue on track to build Schering- Plough into a company with the strength and breadth to deliver long-term high performance. We are moving from survive mode into thrive mode.
building energizing key strength
We are building strength through transforming and energizing our key brands.
active pipeline recognize
We are very active because we recognize we have a late-stage pipeline gap.
changes continues designed finance further global role strengthen
These changes are designed to further strengthen the global finance team, which continues to play an important role in the transformation of Schering- Plough.
allow build changes customers drive edge focus growth manage needs speed
These changes allow us to focus even more effectively on the needs of our customers in different markets, to better manage and drive growth and to build a competitive edge through innovation, speed and flexibility.
achieving delivered earnings full growth promise turnaround
We have delivered on our promise of achieving a turnaround in 1998 and double-digit earnings growth for the full year,
achieving again annual began continue deliver double driven earnings growth increased promise quarter results sales strong turnaround
We continue to deliver on the promise we made when we began our turnaround in 1997 of achieving annual double digit earnings growth, ... Our results this quarter were again driven by strong growth in the U.S., where prescription sales increased 28 percent.
fourth growth higher quarter registered sales special strong third
We have now registered our fourth consecutive quarter of strong sales growth and our third consecutive quarter of higher earnings, excluding special items,
business captures core focus top
Pharmacia' captures the focus of the new organization as an exceptionally fast-growing core pharmaceuticals business in the top tier of the industry,
competitor determined past progress quarters remain several steady toward
We remain determined to become a high-performance competitor for the long term -- and over the past several quarters we have made steady progress toward that goal.
action ahead beginning business delivering growing moving performance phase record solid three today turnaround
Three years after beginning our Action Agenda, Schering-Plough today is delivering a solid record of performance -- growing our business and moving ahead with the turnaround phase of our six- to eight-year plan.
continues franchise gain major pivotal share states united united-states
Our cholesterol franchise is pivotal and continues to gain share in the United States and other major markets.
continues critical franchise growth
Our cholesterol franchise continues to be a critical growth driver.
eight years challenges
We are building a special capability at Schering-Plough to respond to these and other challenges with innovation, speed and flexibility. We aspire to continue being the company delivering the most positive change of any in our peer group, as we work to deliver our Turnaround and advance our six- to eight-year Action Agenda for transformational change.